The overall goal of The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Molecular and Functional Imaging (CMFI) Program is to integrate molecular and functional imaging with translational applications in cancer discovery, drug development and treatment. The CMFI Program has been a developing Program of the Comprehensive Center Support Grant at the SKCCC for five years and has grown from ten to 25 faculty members representing five departments of the School of Medicine. Faculty members hold appointments in four different graduate programs. Twenty faculty members have peer reviewed funding. A majority of the faculty is housed in the CRBI/II complex and the Program is home to roughly ten graduate students and 15 Postdoctoral fellows. The Program is supported by $9.2 million of NCI and other peer reviewed support. The Program contains four highly integrated themes: 1) cancer biology and discovery;2) imaging probe development;3) biomarkers and clinical evaluation of therapies;and 4) target delineation and drug delivery, which are highly interactive with disease-based Programs within the SKCCC. The central goal of the CMFI Program is to use molecular and functional imaging in the diagnosis and treatment of cancer. A major goal of the clinical translational component involves the clinical evaluation of therapies and theranostic imaging. The Program has major interactions with the Breast Cancer, Prostate Cancer, Neuro-oncology, and Hematologic Malignancy/BMT Programs. The total number of publications in the CMFI Program from 2006-2010 is 296 of which 92 (31%) are Intra-Programmatic and 63 (21%) are Inter- Programmatic. Lay: The Cancer Molecular and Functional Imaging Program integrates molecular and functional imaging into cancer research to inform discovery and translational applications into diagnosis, therapy and drug development. The CMFI Program contains four highly integrated themes: 1) cancer biology and discovery;2) imaging probe development;3) biomarkers and clinical evaluation of therapies;and 4) target delineation and drug delivery, which are highly interactive with disease-based Programs within the SKCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661010
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$199,755
Indirect Cost
$76,700
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications